Angina pectoris is a medical term that refers to chest pain or distress affected by coronary heart disease. Angina pectoris develops when the heart muscle does not receive enough blood. This condition typically begins when one or more of the heart’s arteries narrows or becomes blocked, a condition called ischemia. Angina pectoris causes discomfort in the center of the chest, such as pressure, fullness, pain, or squeezing. Smoking, exposure to extremely hot or cold temperatures, emotional stress, or large meals are all factors that might cause stable angina pectoris. An electrocardiogram and angiography can be used to diagnose angina pectoris, which can then be treated with medication, a change in lifestyles, or surgery. Angina pectoris also is treated with angioplasty, a minimally invasive procedure. Complete rest and nitroglycerin are used to treat the discomfort or pain induced by angina pectoris. Nitroglycerin lowers the coronary arteries and other blood vessels by boosting blood supply to the heart vessels.
For Requesting a Sample Copy of This Report, Please Visit @
https://www.coherentmarketinsights.com/insight/request-sample/1158
The global angina pectoris treatment market is expected to grow due to new product releases and a robust pipeline during the forecast period.
Espero announced that it has obtained U.S. Food and Drug Administration (FDA) approval in June 2016 for GoNitro (nitroglycerin) oral powder for acute treatment of angina pectoris or prophylaxis of angina pectoris owing to coronary artery disease. AstraZeneca sold the rights to its two drugs, Plendil and Imdur, for US$ 500 million in February 2016. China Medical System Holdings (CMS) paid AstraZeneca US$ 310 million for Plendil (felodipine) commercialization rights in China. Plendil is a calcium antagonist that is used to treat hypertension as well as to prevent chronic stable angina pectoris. However, Imdur is an oral extended-release formulation of isosorbide mononitrate that is recommended for the anticipation of angina pectoris caused by coronary artery disease. Moreover, Amgen at the Annual Scientific Session in 2015, announced Corlanor (Ivabradine) in its pipeline (phase 3) for treating angina pectoris. At the Annual American Heart Association Meeting in New Orleans in November 2016, Allergan also announced new data on BYSTOLIC (nebivolol) for treating hypertension to reduce blood pressure. Whereas, Perrigo reported in 2013 that the U.S. Food and Drug Administration (FDA) had approved its Abbreviated New Drug Application (ANDA) for Nitroglycerin Lingual Spray, the generic version of Shionogi’s Nitrolingual Pumpspray recommended for prophylaxis of angina pectoris and acute attacks.
Factors such as rising number of collaborations, product launches, and acquisitions and mergers are propelling the global angina pectoris treatment market growth. For instance, in 2017, Recordati acquired AstraZeneca’s blood pressure brand Metoprolol, a beta-blocker used mostly for diseases such as heart disorders, angina pectoris, and hypertension. Furthermore, Lupin Pharmaceuticals received U.S. Food and Drug Administration (FDA) approval in 2017 to develop a generic version of WorldMeds’ nadolol drug, which is recommended for the treatment of angina pectoris and hypertension. Furthermore, the patent expiration of Gilead Sciences, Inc.’s Ranolazine medicine in 2019 will create an opportunity for generic drugs companies in the global angina pectoris treatment market.
Some of the major players contributing to the global market of angina pectoris treatment market are Pfizer Inc., Astra Zeneca plc, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Allergan plc, Novartis AG, Bayer AG, Sanofi SA, Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Gilead Sciences, Inc.
Request a PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/1158
Reasons to Purchase this Report
• Current and future of global Angina Pectoris Treatment market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Content
Global Angina Pectoris Treatment Market Research Report
Section 1: Global Angina Pectoris Treatment Industry Overview
Section 2: Global Economic Impact on Angina Pectoris Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Angina Pectoris Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837